Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy
- 26 October 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Endocrinology
- Vol. 6 (12), 676-688
- https://doi.org/10.1038/nrendo.2010.189
Abstract
Glycogen storage disease type I (GSD-I) consists of a group of autosomal recessive disorders that cause metabolic abnormalities and/or myeloid dysfunction. This Review addresses the etiology of GSD-Ia and GSD-Ib and of glucose-6-phosphatase-β deficiency and highlights advances in diagnosis and treatment, including transplantation and gene therapy. Glycogen storage disease type I (GSD-I) consists of two subtypes: GSD-Ia, a deficiency in glucose-6-phosphatase-α (G6Pase-α) and GSD-Ib, which is characterized by an absence of a glucose-6-phosphate (G6P) transporter (G6PT). A third disorder, G6Pase-β deficiency, shares similarities with this group of diseases. G6Pase-α and G6Pase-β are G6P hydrolases in the membrane of the endoplasmic reticulum, which depend on G6PT to transport G6P from the cytoplasm into the lumen. A functional complex of G6PT and G6Pase-α maintains interprandial glucose homeostasis, whereas G6PT and G6Pase-β act in conjunction to maintain neutrophil function and homeostasis. Patients with GSD-Ia and those with GSD-Ib exhibit a common metabolic phenotype of disturbed glucose homeostasis that is not evident in patients with G6Pase-β deficiency. Patients with a deficiency in G6PT and those lacking G6Pase-β display a common myeloid phenotype that is not shared by patients with GSD-Ia. Previous studies have shown that neutrophils express the complex of G6PT and G6Pase-β to produce endogenous glucose. Inactivation of either G6PT or G6Pase-β increases neutrophil apoptosis, which underlies, at least in part, neutrophil loss (neutropenia) and dysfunction in GSD-Ib and G6Pase-β deficiency. Dietary and/or granulocyte colony-stimulating factor therapies are available; however, many aspects of the diseases are still poorly understood. This Review will address the etiology of GSD-Ia, GSD-Ib and G6Pase-β deficiency and highlight advances in diagnosis and new treatment approaches, including gene therapy.This publication has 131 references indexed in Scilit:
- Complete Normalization of Hepatic G6PC Deficiency in Murine Glycogen Storage Disease Type Ia Using Gene TherapyMolecular Therapy, 2010
- Oxidative stress mediates nephropathy in type Ia glycogen storage diseaseLaboratory Investigation, 2010
- Neutropenia in type Ib glycogen storage diseaseCurrent Opinion in Hematology, 2010
- Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib miceJournal of Hepatology, 2009
- A Syndrome with Congenital Neutropenia and Mutations inG6PC3New England Journal of Medicine, 2009
- Functional analysis of mutations in the glucose-6-phosphate transporter that cause glycogen storage disease type IbMolecular Genetics and Metabolism, 2008
- Mutations in the glucose-6-phosphatase-α (G6PC) gene that cause type Ia glycogen storage diseaseHuman Mutation, 2008
- Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type IaJournal of Hepatology, 2008
- Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type IaKidney International, 2008
- Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib miceGene Therapy, 2006